In countries worldwide, shortages of first-line antibiotics often lead to overuse of those that are specialized or kept in reserve for emergencies. Not only may these substitutes be less effective, but reliance on them increases the risk of drug resistance developing and infections becoming more difficult to treat in the long run.
GENEVA – The overuse of antibiotics is now widely recognized as one of the main factors contributing to antimicrobial resistance – often called the “silent pandemic.” But what is less well known is that shortages of antibiotics also play a role in fueling AMR.
Scarce supplies of pediatric amoxicillin, used to treat Strep A, made headlines in the United Kingdom late last year, as a surge of infections left at least 19 children dead. Far from being an outlier, however, such shortfalls are common and pervasive, affecting countries across the world, and their consequences for both individuals’ health and AMR’s spread can be dire. That is because shortages of first-line antibiotics often lead to overuse of those that are specialized or kept in reserve for emergencies. Not only may these substitutes be less effective, but reliance on them increases the risk of drug resistance developing and infections becoming more difficult to treat in the long run.
Already one of the world’s biggest killers, AMR is on the rise. In 2019, it was directly responsible for an estimated 1.27 million deaths – more than HIV/AIDS and malaria combined – and associated with 4.95 million more. So far, the global response to this growing crisis has focused mainly on trying to outpace drug-resistant bacteria through the development of new antibiotics. But in the short term, there is ample room to reduce the number of AMR deaths, as well as AMR’s impact on health more broadly, by addressing some of the causes of shortages and improving access to appropriate treatments.
GENEVA – The overuse of antibiotics is now widely recognized as one of the main factors contributing to antimicrobial resistance – often called the “silent pandemic.” But what is less well known is that shortages of antibiotics also play a role in fueling AMR.
Scarce supplies of pediatric amoxicillin, used to treat Strep A, made headlines in the United Kingdom late last year, as a surge of infections left at least 19 children dead. Far from being an outlier, however, such shortfalls are common and pervasive, affecting countries across the world, and their consequences for both individuals’ health and AMR’s spread can be dire. That is because shortages of first-line antibiotics often lead to overuse of those that are specialized or kept in reserve for emergencies. Not only may these substitutes be less effective, but reliance on them increases the risk of drug resistance developing and infections becoming more difficult to treat in the long run.
Already one of the world’s biggest killers, AMR is on the rise. In 2019, it was directly responsible for an estimated 1.27 million deaths – more than HIV/AIDS and malaria combined – and associated with 4.95 million more. So far, the global response to this growing crisis has focused mainly on trying to outpace drug-resistant bacteria through the development of new antibiotics. But in the short term, there is ample room to reduce the number of AMR deaths, as well as AMR’s impact on health more broadly, by addressing some of the causes of shortages and improving access to appropriate treatments.